Art. -Nr.: HY-10502

Tipifarnib

(Synonyms: IND 58359; R115777)

14 Cited Publications

Kundenbewertung

Based on 14 publication(s) in Google Scholar

Tipifarnib (IND 58359) binds to and inhibits farnesyltransferase (FTase) with an IC₅₀ of 0.86 nM. Antineoplastic activity and antiparasitic activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.72%
CAS. Nr.: 192185-72-1
Formel: C₂₇H₂₂Cl₂N₄O
Molecular Weight:489.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Tipifarnib Chemical Structure

CAS. Nr.: 192185-72-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (14)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Tipifarnib (IND 58359) binds to and inhibits farnesyltransferase (FTase) with an IC₅₀ of 0.86 nM. Antineoplastic activity and antiparasitic activity^[1].

IC₅₀ & Target

IC50: 0.86 nM (FTase)

Cellular Effect

Cell Line	Type	Value	Description	References
Capan-2	IC₅₀	16 nM Compound: 59	Antiproliferative activity against human Capan-2 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days Antiproliferative activity against human Capan-2 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days	[PMID: 33228976]
HCT-116	EC₅₀	24 nM Compound: R115777	Inhibition of anchorage-independent growth in human HCT-116 cells assessed as inhibition of colony formation incubated for 14 days in presence of 10% FBS by imaging based soft agar colony formation assay Inhibition of anchorage-independent growth in human HCT-116 cells assessed as inhibition of colony formation incubated for 14 days in presence of 10% FBS by imaging based soft agar colony formation assay	[PMID: 16222147]
HepG2	CC₅₀	30 μM Compound: Tipifarnib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based spectraMax M5 microplate reader analysis Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based spectraMax M5 microplate reader analysis	[PMID: 39051854]
HT1197	IC₅₀	1.7 nM Compound: 59	Antiproliferative activity against human HT1197 cells harboring HRAS 61 mutation assessed as inhibition of cell growth incubated for 4 to 7 days Antiproliferative activity against human HT1197 cells harboring HRAS 61 mutation assessed as inhibition of cell growth incubated for 4 to 7 days	[PMID: 33228976]
MCF7	IC₅₀	3.08 μM Compound: R115777	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	10.1039/C3MD00058C
NCI-H441	IC₅₀	36 nM Compound: 59	Antiproliferative activity against human NCI-H441 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days Antiproliferative activity against human NCI-H441 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days	[PMID: 33228976]
NIH3T3	EC₅₀	0.002 μM Compound: 1, R-115777	Effective concentration against Ha-RAS processing in NIH3T3 ras-transformed cells Effective concentration against Ha-RAS processing in NIH3T3 ras-transformed cells	[PMID: 12657284]
NIH3T3	EC₅₀	1.6 nM Compound: 1	Inhibition of Ras processing in H-ras transformed NIH3T3 cells in presence of Tipifarnib Inhibition of Ras processing in H-ras transformed NIH3T3 cells in presence of Tipifarnib	[PMID: 15911281]
NIH3T3	EC₅₀	1.6 nM Compound: 1 (Tipifarnib)	Inhibition of H-Ras transformed NIH-3T3-cell proliferation Inhibition of H-Ras transformed NIH-3T3-cell proliferation	[PMID: 15454229]
NIH3T3	EC₅₀	1.6 nM Compound: Tipifarnib	Inhibition of Ras farnesylation in H-Ras transformed NIH3T3 cells Inhibition of Ras farnesylation in H-Ras transformed NIH3T3 cells	[PMID: 15454228]
NIH3T3	EC₅₀	100 nM Compound: 1	Inhibition of Ras processing in H-ras transformed NIH3T3 cells in presence of Lonafarnib Inhibition of Ras processing in H-ras transformed NIH3T3 cells in presence of Lonafarnib	[PMID: 15911281]
NIH3T3	EC₅₀	3.7 nM Compound: R115777	Inhibition of anchorage-independent growth in H-Ras transformed mouse NIH3T3 cells assessed as inhibition of colony formation incubated for 14 days in presence of 10% bovine serum by imaging based soft agar colony formation assay Inhibition of anchorage-independent growth in H-Ras transformed mouse NIH3T3 cells assessed as inhibition of colony formation incubated for 14 days in presence of 10% bovine serum by imaging based soft agar colony formation assay	[PMID: 16222147]
NIH3T3	EC₅₀	4 nM Compound: 1	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 7 days by alamar blue assay Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 7 days by alamar blue assay	[PMID: 20429511]
NIH3T3	EC₅₀	4 nM Compound: 1	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in mouse 3T3 cells Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in mouse 3T3 cells	[PMID: 19875282]
NIH3T3	IC₅₀	1.7 nM Compound: 1	T24H-ras-transformed NIH3T3 cell proliferation T24H-ras-transformed NIH3T3 cell proliferation	[PMID: 14643327]
NIH3T3	IC₅₀	1.7 nM Compound: 1, R-115777	Inhibition of T24F1H-ras-transformation in NIH 3T3 cells Inhibition of T24F1H-ras-transformation in NIH 3T3 cells	[PMID: 12699751]
NIH3T3	IC₅₀	1.7 nM Compound: R-11577	In vitro inhibition of NIH3T3 cell proliferation In vitro inhibition of NIH3T3 cell proliferation	[PMID: 14643326]
Sf9	IC₅₀	0.7 nM Compound: 1	Inhibition of rat recombinant protein farnesyltransferase expressed in Sf9 cells by [3H]-scintillation proximity assay Inhibition of rat recombinant protein farnesyltransferase expressed in Sf9 cells by [3H]-scintillation proximity assay	[PMID: 19239254]
Sf9	IC₅₀	0.7 nM Compound: 1	Inhibition of rat recombinant PFT expressed in insect Sf9 cells by scintillation proximity assay Inhibition of rat recombinant PFT expressed in insect Sf9 cells by scintillation proximity assay	[PMID: 20429511]
SU.86.86	IC₅₀	9.5 nM Compound: 59	Antiproliferative activity against human SU-86-86 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days Antiproliferative activity against human SU-86-86 cells harboring KRAS 12 mutation assessed as inhibition of cell growth incubated for 4 to 7 days	[PMID: 33228976]

In Vitro

Tipifarnib is a potent inhibitor of Trypanosoma Cruzi with the ED₅₀ of 4 nM^[1].
Tipifarnib inhibits isolated human farnesyltransferase for a lamin B peptide and for the K-RasB peptide with IC₅₀ of 0.86 nM and 7.9 nM, respectively^[2].
Tipifarnib shows inhibition of cell growth or angiogenesis, and induction of apoptosis in aggressive prostate cancer (PCa)^[3].
Tipifarnib (0.25 μM, 1 μM; 48 h) shows a significant decrease in the concentration of exosomes in C4-2B cells and PC-3 cells^[3].
Tipifarnib (1 μM) significantly inhibits the protein concentration of Alix, nSMase2, and Rab27a in C4-2B cells^[3].
Tipifarnib (0.25 μM) significantly inhibits the activation of p-ERK (downstream effector molecule of the Ras/Raf/ERK signaling pathway) but not total ERK in C4-2B and PC-3 cells^[3].
Tipifarnib (1.25-5 μM; 30 min) promotes endoplasmic reticulum stress in U937 cells, resulting in dysregulation of intracellular calcium homeostasis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tipifarnib (10 mg/kg; ip; single dose) upregulated antiapoptotic protein, Bcl-xL in liver, and prevents mosue death induced by GalN/LPS^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

GalN/LPS challenge mouse^[5]
Dosage:

10 mg/kg; while chanllenge with GalN (400 mg/kg; IP) and LPS (32 g/kg)
Administration:

IP; 60 min before challenge
Result:

Protected primary hepatocytes from GalN/tumor necrosis factor-induced cell death.
Inhibited caspase 3 activation and upregulating antiapoptotic proteins.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 192185-72-1
Appearance Solid
Molecular Weight 489.40
Formel C₂₇H₂₂Cl₂N₄O
Color White to light yellow
SMILES

O=C1N(C2=C(C(C3=CC=CC(Cl)=C3)=C1)C=C(C=C2)[C@@](N)(C4=CN=CN4C)C5=CC=C(C=C5)Cl)C
Synonyms

IND 58359; R115777
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (14)

All WBIn Vivo Efficacy StudyIn Vivo ImagingIFRT-PCRHistological Imaging/Staining

Sort by:

Journal Impact Factor

Cancer Res

The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition. [Abstract]

2026 Feb 9. PMID: 41661652
Circ Res

Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure. [Abstract]

2024 Jul 5;135(2):280-297. PMID: 38847080

Tipifarnib purchased from MedChemExpress. Usage Cited in: Circ Res. 2024 Jul 5;135(2):280-297. [Abstract]

Representative image of the western blotting analyses of protein extracted from mouse hearts to study the effect of Tipifarnib (10 mg/kg body weight/three times a week, IP injection) treatment on the expression of proteins involved in exosome biogenesis. GAPDH served as the loading control.

Tipifarnib purchased from MedChemExpress. Usage Cited in: Circ Res. 2024 Jul 5;135(2):280-297. [Abstract]

Post TAC, heart-to-body weight ratio (HW/BW) and Heart weight (HW) to Tibia length (TL) (gm/cm) ratio at 8 weeks for sham, TAC and TAC+Tipifarnib (10 mg/kg body weight/three times a week, IP injection). Data are expressed as Mean ± SEM. Mean of the different groups was compared using one-way ANOVA followed by Tukey post-tests. with 95% confidence interval.

Tipifarnib purchased from MedChemExpress. Usage Cited in: Circ Res. 2024 Jul 5;135(2):280-297. [Abstract]

Representative echocardiographic images (M-mode) from sham, TAC and Tipifarnib (10 mg/kg body weight/three times a week, IP injection) treated TAC mouse heart at 8 weeks.

Tipifarnib purchased from MedChemExpress. Usage Cited in: Circ Res. 2024 Jul 5;135(2):280-297. [Abstract]

Tipifarnib (10 mg/kg body weight/three times a week, IP injection). Representative image of the immunofluorescence of myocardial sections stained with Alexa fluor 488-labeled wheat germ agglutinin (WGA) antibody, defining myocyte boundaries. Scale bar = 50 μm).

Tipifarnib purchased from MedChemExpress. Usage Cited in: Circ Res. 2024 Jul 5;135(2):280-297. [Abstract]

Tipifarnib (10 mg/kg body weight/three times a week, IP injection). Quantitative Reverse Transcription Polymerase Chain Reaction (qRT PCR) of mice heart tissues for hypertrophy–related genes (ANP, BNP and MYH7) in each experimental group after 8 weeks post-TAC; n=7/group.

Tipifarnib purchased from MedChemExpress. Usage Cited in: Circ Res. 2024 Jul 5;135(2):280-297. [Abstract]

Representative image for Masson’s trichrome staining in the heart tissues of sham, TAC and Tipifarnib (10 mg/kg body weight/three times a week, IP injection) treated TAC (TAC+Tipifarnib) Scale bar = 50 μm.
Mol Cell

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. [Abstract]

2021 Oct 7;81(19):4076-4090.e8. PMID: 34375582
Mol Cell

The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. [Abstract]

2021 Jul 1;81(13):2736-2751.e8. PMID: 33932349
J Clin Invest

Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment. [Abstract]

2025 Jul 15;135(14):e189048. PMID: 40662365
J Immunother Cancer

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. [Abstract]

2022 Apr;10(4):e004399. PMID: 35483745
Br J Cancer

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. [Abstract]

2024 Apr;130(6):1059-1072. PMID: 38278976
Plant Cell Environ

Isoprenylation modification is required for HIPP1-mediated powdery mildew resistance in wheat. [Abstract]

2023 Jan;46(1):288-305. PMID: 36319595
Biochem Pharmacol

An updated review on the inhibition of exosome biogenesis, release, and uptake: a potential anticancer approach. [Abstract]

2025 Sep:239:117019. PMID: 40499840
Mol Plant Pathol

The farnesyltransferase β-subunit RAM1 regulates localization of RAS proteins and appressorium-mediated infection in Magnaporthe oryzae. [Abstract]

2019 Sep;20(9):1264-1278. PMID: 31250536
iScience

Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. [Abstract]

2025 Jan 21;28(2):111864. PMID: 39995872
Mol Biol Rep

Role of Acorus calamus extract in reducing exosome secretion by targeting Rab27a and nSMase2: a therapeutic approach for breast cancer. [Abstract]

2025 Jan 15;52(1):124. PMID: 39812915
Extracell Vesicle

2025 Jun.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (68.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0433 mL

10.2167 mL

20.4334 mL

5 mM

0.4087 mL

2.0433 mL

4.0867 mL

10 mM

0.2043 mL

1.0217 mL

2.0433 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% HP-β-CD/10 mM Citrate pH 2.0

Solubility: 10 mg/mL (20.43 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Devendra S Puntambekar, et al. Inhibition of farnesyltransferase: a rational approach to treat cancer? J Enzyme Inhib Med Chem. 2007 Apr;22(2):127-40. [Content Brief]

[2]. End DW, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1;61(1):131-7 [Content Brief]

[3]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0433 mL	10.2167 mL	20.4334 mL	51.0834 mL
	5 mM	0.4087 mL	2.0433 mL	4.0867 mL	10.2167 mL
	10 mM	0.2043 mL	1.0217 mL	2.0433 mL	5.1083 mL
	15 mM	0.1362 mL	0.6811 mL	1.3622 mL	3.4056 mL
	20 mM	0.1022 mL	0.5108 mL	1.0217 mL	2.5542 mL
	25 mM	0.0817 mL	0.4087 mL	0.8173 mL	2.0433 mL
	30 mM	0.0681 mL	0.3406 mL	0.6811 mL	1.7028 mL
	40 mM	0.0511 mL	0.2554 mL	0.5108 mL	1.2771 mL
	50 mM	0.0409 mL	0.2043 mL	0.4087 mL	1.0217 mL
	60 mM	0.0341 mL	0.1703 mL	0.3406 mL	0.8514 mL

Keywords

Tipifarnib

14 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tipifarnib

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Endoplasmic Reticulum Stress Compound Library

FDA Approved & Pharmacopeial Drug Library

Exosomes Compound Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Targeted Diversity Library

Rare Diseases Drug Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Tipifarnib

Biologische Aktivität

Chemical Information

Publications (14)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tipifarnib

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Endoplasmic Reticulum Stress Compound Library

FDA Approved & Pharmacopeial Drug Library

Exosomes Compound Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Targeted Diversity Library

Rare Diseases Drug Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Tipifarnib

Biologische Aktivität

Chemical Information

Publications (14)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tipifarnib Related Classifications

HY-10502 Related Classifications